HOME >> MEDICINE >> NEWS
Survival benefit for rheumatoid arthritis patients treated with methotrexate

The anticancer drug methotrexate could have a substantial survival benefit among patients with rheumatoid arthritis, conclude authors of a prospective US study in this weeks issue of THE LANCET.

Rheumatoid arthritis is a chronic inflammatory disease which results in reduced life-expectancy and is associated with cardiovascular disease, infection, and cancer. Low-dose methotrexate is the main choice of antirheumatic therapy for rheumatoid arthritis, although its effect on mortality for patients with the disease is not known.

Hyon Choi from Harvard Medical School and Harvard School of Public Health, Frederick Wolfe from University of Kansas School of Medicine, USA, and colleagues prospectively studied 1240 patients with rheumatoid arthritis over the past two decades. 191 individuals died during follow-up. Patients who began treatment with methotrexate (around half of the study population) had more severe rheumatoid arthritis. After adjustment for this confounding factor, methotrexate was found to have a 60% survival benefit for all-cause mortality compared with those who did not use methotrexate, and a 70% survival benefit for cardiovascular death.

Hyon Choi comments: Our data indicate that methotrexate may provide a substantial survival benefit, largely by reducing cardiovascular mortality. This gain in life expectancy could be considered in selecting a cost-effective, disease-modifying antirheumatic drug on a long-term basis. Additionally, the survival benefit of methotrexate would set a standard against which new disease-modifying antirheumatic drugs should be compared.


'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-0-20-7424-4949
Lancet
4-Apr-2002


Page: 1

Related medicine news :

1. Survival sex and substance abuse may hinder HIV prevention efforts
2. Survival improves in clinical trial for severe birth defect, with or without fetal surgery
3. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
4. American Heart Association Comment: Contributions Of Trends In Survival And Coronary-Event Rates To Changes In Coronary Heart Disease Mortality
5. Early Heart Repair For Marfan Syndrome Patients Critical To Survival
6. Intensive Care Before A Major Op May Improve Survival
7. Sex And Survival: In Some Matters Of The Heart Women Have The Edge
8. Study: Birth Defects Decrease Survival, Childbirth, Boost Risk Of Similar Defects
9. Study Indicates That Medicare Costs Are Higher -- And Survival Rate Is Better --At Major Teaching Hospitals Survive Climate Change
10. Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients
11. Beta Blocker Significantly Improves Heart Failure Survival

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... September 22, 2017 , ... ... other tick-borne diseases through research, education and awareness, today announced the appointment of ... immunologist and microbiologist, Dr. Sellati has more than 20 years of research experience ...
(Date:9/21/2017)... ... ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center is Saluted as Young ... Plastic Surgeon Kiranjeet Gill has been awarded as one of the 15th annual 40-under-40 ... was started in 2003 to salute young achievers in Southwest Florida who have distinguished ...
(Date:9/21/2017)... ... 2017 , ... SABRE is raising awareness about personal safety with a Chicago ... November. , The Chicago, Illinois, based self-defense brand has been waiting for an opportunity ... of taking their personal safety into their own hands. , The ads focus on ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and ... while staying in compliance with FDA rules. , The FDA has issued two ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent and ... departments have been awarded five-year accreditation status through the Public Health Accreditation ... served by a PHAB-accredited health department now extend to more than 203 ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... BOTHELL, Wash. , Sept. 7, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), announces that Mike Rice , President and ... Rodman & Renshaw 19 th ... 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology:
Cached News: